1-20 of 245
tocilizumab
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

An ounce of which prevention is worth a…?

Joerg Halter, Jakob Passweg
Journal: Blood
Blood (2021) 137 (14): 1852–1853.
https://doi.org/10.1182/blood.2021010688
Published: 2021
Journal Articles

A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis

Clinical Trials & Observations
Glen A. Kennedy, Siok-Keen Tey, Luke Buizen, Antiopi Varelias, Kate H. Gartlan, Cameron Curley, Stuart D. Olver, Karshing Chang, Jason P. Butler, Ashish Misra, Elango Subramoniapillai, A. James Morton, Simon Durrant, Andrea S. Henden, John Moore, David Ritchie, David Gottlieb, Julian Cooney, Sanjoy K. Paul, Geoffrey R. Hill
Journal: Blood
Blood (2021) 137 (14): 1970–1979.
https://doi.org/10.1182/blood.2020009050
Published: 2021
Includes: Supplemental data
Journal Articles

DARTs point the way forward in AML

Clinical Trials & Observations
Saar Gill
Journal: Blood
Blood (2021) 137 (6): 720–721.
https://doi.org/10.1182/blood.2020009020
Published: 2021
Journal Articles

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Clinical Trials & Observations
Geoffrey L. Uy, Ibrahim Aldoss, Matthew C. Foster, Peter H. Sayre, Matthew J. Wieduwilt, Anjali S. Advani, John E. Godwin, Martha L. Arellano, Kendra L. Sweet, Ashkan Emadi, Farhad Ravandi, Harry P. Erba, Michael Byrne, Laura Michaelis, Max S. Topp, Norbert Vey, Fabio Ciceri, Matteo Giovanni Carrabba, Stefania Paolini, Gerwin A. Huls, Mojca Jongen-Lavrencic, Martin Wermke, Patrice Chevallier, Emmanuel Gyan, Christian Récher, Patrick J. Stiff, Kristen M. Pettit, Bob Löwenberg, Sarah E. Church, Erica Anderson, Jayakumar Vadakekolathu, Marianne Santaguida, Michael P. Rettig, John Muth, Teia Curtis, Erin Fehr, Kuo Guo, Jian Zhao, Ouiam Bakkacha, Kenneth Jacobs, Kathy Tran, Patrick Kaminker, Maya Kostova, Ezio Bonvini, Roland B. Walter, Jan K. Davidson-Moncada, Sergio Rutella, John F. DiPersio
Journal: Blood
Blood (2021) 137 (6): 751–762.
https://doi.org/10.1182/blood.2020007732
Published: 2021
Includes: Supplemental data
Journal Articles

Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?

Clinical Trials & Observations
Matthew J. Frigault, Sarah Nikiforow, Michael K. Mansour, Zhen-Huan Hu, Mary M. Horowitz, Marcie L. Riches, Peiman Hematti, Cameron J. Turtle, Mei-Jie Zhang, Miguel-Angel Perales, Marcelo C. Pasquini
Journal: Blood
Blood (2020) 136 (1): 137–139.
https://doi.org/10.1182/blood.2020006216
Published: 2020
Journal Articles

Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus–associated multicentric Castleman disease

Clinical Trials & Observations
Ramya Ramaswami, Kathryn Lurain, Cody J. Peer, Anna Serquiña, Victoria Wang, Anaida Widell, Priscila Goncalves, Seth M. Steinberg, Vickie Marshall, Jomy George, William D. Figg, Denise Whitby, Joseph Ziegelbauer, Thomas S. Uldrick, Robert Yarchoan
Journal: Blood
Blood (2020) 135 (25): 2316–2319.
https://doi.org/10.1182/blood.2019004602
Published: 2020
Includes: Supplemental data
Journal Articles

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy

Rebecca A. Gardner, Francesco Ceppi, Julie Rivers, Colleen Annesley, Corinne Summers, Agne Taraseviciute, Juliane Gust, Kasey J. Leger, Katherine Tarlock, Todd M. Cooper, Olivia C. Finney, Hannah Brakke, Daniel H. Li, Julie R. Park, Michael C. Jensen
Journal: Blood
Blood (2019) 134 (24): 2149–2158.
https://doi.org/10.1182/blood.2019001463
Published: 2019
Includes: Supplemental data
Journal Articles

The earlier the better: timely mitigation of CRS

Rayne H. Rouce
Journal: Blood
Blood (2019) 134 (24): 2119–2120.
https://doi.org/10.1182/blood.2019003618
Published: 2019
Journal Articles

Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)

Marcelo C. Pasquini, MDMS, Frederick L. Locke, MD, Alex F. Herrera, MD, Tanya Siddiqi, MD, Armin Ghobadi, MD, Krishna V Komanduri, MD, Zhen-Huan Hu, MPH, Hua Dong, PhD, Peiman Hematti, MD, Sarah Nikiforow, MD PhD, Patricia Steinert, PhD, Anna Purdum, PharmD,MS, Mary M. Horowitz, Michelle Hooper, Jun Kawashima, MD, Caron A. Jacobson, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 764.
https://doi.org/10.1182/blood-2019-124750
Published: 2019
Journal Articles

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry

Samantha Jaglowski, MD, Zhen-Huan Hu, MPH, Yiyun Zhang, PhD, Manali Kamdar, MD, Monalisa Ghosh, Premal Lulla, MBBS, Joshua Sasine, MD PhD, Miguel-Angel Perales, MD, Peiman Hematti, MD, Sarah Nikiforow, MD PhD, Patricia Steinert, PhD, Margit Jeschke, PhD, Lan Yi, PhD, Raghav Chawla, MD PhD, Lida Pacaud, Mary M. Horowitz, Eric Bleickardt, MD, Marcelo C. Pasquini, MDMS
Journal: Blood
Blood (2019) 134 (Supplement_1): 766.
https://doi.org/10.1182/blood-2019-130983
Published: 2019
Journal Articles

Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium

N. Nora Bennani, MD, Matthew J. Maurer, MS, Loretta J. Nastoupil, MD MSc, Michael D. Jain, MD PhD, Julio C. Chavez, MD, Amanda F Cashen, MD, Saurabh Dahiya, MD, Lazaros J. Lekakis, MD, Patrick M Reagan, MD, Olalekan O. Oluwole, MBBS, MPH, Joseph P. McGuirk, DO, Abhinav Deol, MD, Alison R. Sehgal, MD, Andre Goy, MD, Brian T. Hill, MD, Khoan Vu, MD, Charalambos Andreadis, MD, Javier Munoz, MD MS, FACP, Aaron P. Rapoport, Julie M Vose, MDMBA, David B Miklos, MD PhD, Frederick L. Locke, MD, Sattva S Neelapu, MD, Yi Lin, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 763.
https://doi.org/10.1182/blood-2019-129097
Published: 2019
Journal Articles

Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Paolo Strati, MD, Sudhakar Tummala, Loretta J. Nastoupil, MD MSc, Jason R. Westin, MD, Luis Fayad, MD, Sairah Ahmed, MD, Nathan H. Fowler, MD, F. B. Hagemeister, MD, Hun Ju Lee, MD, Swaminathan P. Iyer, MD, Ranjit Nair, MD, Simrit Parmar, MBBS, Maria Alma Rodriguez, MD, Felipe Samaniego, MD, Raphael Eric Steiner, MD, Michael L. Wang, MD, Chelsea Camille Pinnix, MD PhD, Sherry Adkins, ANP, Catherine M. Claussen, MS, Charles Martinez, Misha Hawkins, Nicole Johnson, Shirley George, Sattva S Neelapu, MD, Linda Chi, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 765.
https://doi.org/10.1182/blood-2019-125769
Published: 2019
Journal Articles

Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy

Jesus G. Berdeja, MD, Melissa Alsina, MD, Nina D. Shah, MD, David S. Siegel, Sundar Jagannath, MD, Deepu Madduri, MD, Jonathan L. Kaufman, MD, Nikhil C. Munshi, MD, Jacalyn Rosenblatt, MD, Jagoda K. Jasielec, MD, Yi Lin, MD PhD, Ashley Turka, Lyh Ping Lam, PharmD, RPh, Monica Massaro, MPH, Timothy B. Campbell, MD PhD, Kristen Hege, Fabio Petrocca, MD, Noopur S. Raje, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 927.
https://doi.org/10.1182/blood-2019-126660
Published: 2019
Journal Articles

A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial

Chenggong Li, Heng Mei, Yu Hu, MD PhD, Tao Guo, MD PhD, Lin Liu, MD PhD, Huiwen Jiang, Lu Tang, Yaohui Wu, MD PhD, Lisha Ai, MD PhD, Jun Deng, MD PhD, Dan Jin
Journal: Blood
Blood (2019) 134 (Supplement_1): 930.
https://doi.org/10.1182/blood-2019-130340
Published: 2019
Journal Articles

Exploiting the Zinc Finger Degrome Targeted By Lenalidomide to Engineer Reversible Off-Switch Degradable Chimeric Antigen Receptors

Max Jan, MD PhD, Ana Castano, MD, Amanda Walker, BA, Andrew A Guirguis, MD PhD, Jessica A Gasser, PhD, Amanda A Bouffard, Mikolaj Slabicki, PhD, Alexander Tepper, Daniel E Grinshpun, Taeyoon Kyung, PhD, Quinlan Sievers, MD PhD, Michael E Birnbaum, PhD, Marcela V Maus, MD PhD, Benjamin L. Ebert, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 866.
https://doi.org/10.1182/blood-2019-124210
Published: 2019
Journal Articles

Anti-CD19 CAR T Therapy Following Autologous HSCT May be Safe and Effective in Patients with Refractory Large B-Cell Lymphoma

Wei Liu, Wenyang Huang, Rui Lv, Shuhui Deng, MD, Shuhua Yi, MD, Lugui Qiu, MD PhD, Dehui Zou, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 784.
https://doi.org/10.1182/blood-2019-127659
Published: 2019
Journal Articles

Automated Manufacture of Matched Donor-Derived Allogeneic CD19 CAR T-Cells for Relapsed/Refractory B-ALL Following Allogeneic Stem Cell Transplantation: Toxicity, Efficacy and the Important Role of Lymphodepletion

Claire Roddie, PhD MD, Maeve A O'Reilly, MBBCHBAO, Maria A V Marzolini, Leigh Wood, BA, Juliana Dias Alves Pinto, PhD, Mahnaz Abbasian, Ketki Vispute, Leticia Bosshard, Mark W. Lowdell, BSc, MSc, PhD FRCPath, Graham Wheeler, Alex Day, Bilyana Popova, Kim Champion, Yashma Pathak, Alexia Gali, Nasir Mahmoud, Victoria Spanswick, Helen Lowe, John A. Hartley, PhD, Farzin Farzaneh, PhD, Lauren Nickolay, PhD, Fahetullah Syed, Waseem Qasim, MBBS, PhD, David C. Linch, Martin Pule, Karl S Peggs
Journal: Blood
Blood (2019) 134 (Supplement_1): 776.
https://doi.org/10.1182/blood-2019-129640
Published: 2019
Journal Articles

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)

Veronika Bachanova, MD PhD, David H. McKenna, MD, Xianghua Luo, PhD, Todd E. DeFor, MS, Fiona He, MD, Murali Janakiram, MD MS, Erica D. Warlick, MD, Rose Wangen, Zuzan Cayci, MD, Bartosz Grzywacz, MD, Guy Brachya, PhD, Tony Peled, MSc, Jeffrey S. Miller, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 777.
https://doi.org/10.1182/blood-2019-130476
Published: 2019
Journal Articles

A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas

Peter A. Riedell, MD, Chase Walling, BS, Loretta J. Nastoupil, MD MSc, Martina Pennisi, Richard T. Maziarz, MD, Joseph P. McGuirk, DO, Olalekan O. Oluwole, MBBS, MPH, Veronika Bachanova, MD PhD, Wei-Ting Hwang, PhD, Stephen J. Schuster, MD, Miguel-Angel Perales, MD, Michael R. Bishop, MD, David L. Porter, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1599.
https://doi.org/10.1182/blood-2019-127490
Published: 2019
Journal Articles

Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients Remain

Sheila K Pierson, MS, Yue Ren, Johnson Khor, Eric Haljasmaa, Jasira Ziglar, Katherine Floess, Erin NaPier, Faizaan Akhter, Amy Y Liu, Damilola Gibson, Karan Kanhai, MD PhD, Rabecka Martin, PhD, Amy Chadburn, MD, Gordan Srkalovic, MD PhD, Megan S. Lim, MD PhD, Corey Casper, MD MPH, Thomas S. Uldrick, MD MS, Elaine S. Jaffe, MD, Frits van Rhee, MD PhD, Hongzhe Lee, PhD, David C Fajgenbaum, MDMBA,MSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 1540.
https://doi.org/10.1182/blood-2019-131367
Published: 2019